Summary
Fifteen patients with relapsed osteosarcoma were treated with an intensive combination chemotherapy schedule. Ifosfamide 2.5 g m–2 daily and etoposide 150 mg m–2 daily coincidentally for 3 days and high-dose methotrexate 8 g m–2 (with folinic acid rescue) on days 10–14 in a planned 21-day cycle. Feasibility, toxicity and response to this alternative combination for the treatment of relapsed osteosarcoma was assessed. There were 98 evaluable cycles for toxicity and tolerability. The majority of cycles were well tolerated. Haematological toxicity of grade 3/4 (common toxicity criteria) was seen in all courses. Renal tubular loss of electrolytes, particularly magnesium, occurred in 71% of cycles. Thirteen per cent of cycles were repeated within 21 days and 61% within 28 days. In the thirteen patients evaluable for response, a partial response rate of 31% was seen after two cycles. However, patients with stable disease continued on therapy, and an overall consequent response rate of 62% was observed. Four patients were alive with no evidence of disease at 8–74 months. Three are alive with disease (at 8–19 months). There were six deaths, all disease related. This regimen exhibits an encouraging response rate in a group of children with poor prognosis disease, with a tolerable toxicity profile.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bacci, G., Picci, P., Briccoli, A., Avella, M., Ferrari, S., Femino, F. P., Monti, C., Ruggieri, P., Rizzente, A. & Casadei, R. (1992). Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 78: 200–206.
Bacci, G., Picci, P., Ferrari, S., Ruggieri, P., Casadei, R., Tienghi, A., Brach del Prever, A., Gherlinzoni, F., Mercuri, M. & Monti, C. (1993). Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 72: 3227–3238.
Belli, L., Scholl, S., Livartowski, A., Ashby, M., Palangie, T., Levasseur, P. & Pouillart, P. (1989). Resection of pulmonary metastases in osteosarcoma – a retrospective analysis of 44 patients. Cancer 63: 2546–2550.
Cassano, W., Graham-Pole, J. & Dickson, N. (1991). Etoposide, cyclophosphamide, cisplatin and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 68: 1899–1902.
Chard, R. L. Jr, Krivit, W., Bleyer, W. A. & Hammond, D. (1979). Phase II study of VP16-213 in childhood malignant disease: a Children’s Cancer Study Group report. Cancer Treat Rep 63: 1755–1759.
Chawla, S. P., Rosen, G., Lowenbraun, S., Morton, D. & Eilber, F. (1990). Role of high dose ifosfamide in recurrent osteosarcoma. Proc Am Soc Clin Oncol 9: A1201
Cores, E. P., Holland, J. F., Wang, J. J. & Sinks, L. F. (1972). Doxorubicin in disseminated osteosarcoma. JAMA 221: 1132–1138.
Franklin, H. R., Simonetti, G. P., Dubbelman, A. C., ten Bokkel, H., Huinink, W. W., Taal, B. G., Wigbout, G., Mandjes, I. A., Dalesio, O. B. & Aaronson, N. K. (1994). Toxicity grading system. A comparison between the WHO scoring system and the CTC when used for nausea and vomiting. Ann Oncol 5: 113–117.
Gentet, J. C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., Pillon, P., Bernard, J. L. & Kalifa, C. (1997). Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 33: 232–237.
Goorin, A. M., Delorey, M., Lack, E. E., Gelber, R. D., Price, K., Cassady, J. R., Levey, R., Tapper, D., Jaffe, N., Link, M. & Abelson, H. T. (1984). Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2: 425–431.
Goorin, A. M., Abelson, H. T. & Frei, E. (1985). Osteosarcoma: fifteen years later. N Engl J Med 313: 1637–1643.
Goorin, A. M. & Cantor, A. Link MP for Pediatric Oncology Group, Chicago, IL, USA (1994). A phase I trial of etoposide (VP) and escalating doses of ifosfamide (IFOS) plus GCSF in recurrent pediatric sarcomas. Proc Am Soc Clin Oncol 13: 425
Grana, N., Graham-Pole, J., Cassano, W. F., Gross, S., Mehta, P., Kedar, A., Elfenbein, G. & Oblon, D. (1989). Etoposide (VP-16) infusion plus cyclophosphamide (CY) pulses: an effective combination for refractor cancer (abstract). Proc Am Soc Clin Oncol 8: 300
Grem, J. L., King, S. A., Wittes, R. E. & Leyland-Jones, B. (1988). The role of methotrexate in osteosarcoma. J Natl Cancer Inst 80: 626–636.
Han, M-T, Telander, R. L., Pairolero, P. C., Payne, W. S., Gilchrist, G. S., Sim, F. H. & Pritchard, D. J. (1981). Aggressive thoracotomy for pulmonary metastatic osteogenic sarcoma in children and young adolescents. J Pediatr Surg 16: 928–933.
Harris, M., Cantor, A., Goorin, A. M., Shochat, S., Ayala, A. G., Ferguson, W. S., Holbrook, T. & Link, M. P. (1995). Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group Study. Med Pediatr Oncol 24: 87–92.
Huth, J. F. & Eilber, F. R. (1989). Patterns of recurrence after resection of osteosarcoma of the extremity: strategies for treatment of metastases. Arch Surg 124: 122–126.
Jaffe, N., Farber, S., Paed, D., Farber, S., Traggis, D., Geiser, C., Kim, B. S., Das, L., Frauenberger, G., Djerassi, I. & Cassidy, J. R. (1973). Favourable response of metastatic osteogenic sarcoma to pulse high dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31: 1367–1373.
Kung, F., Hayes, A. & Krischner, J. (1985). VP-16 in children with recurrent malignant solid tumours: a phase II study (abstract). Proc Am Soc Clin Oncol 4: 235
Link, M., Goorin, A., Horowitz, M., Meyer, W., Belasco, J., Baker, A., Ayala, A. & Shuster, J. (1991). Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop 270: 8–14.
Marti, C., Kroner, T., Remagen, W., Berchtold, W., Cserhati, M. & Varini, M. (1985). High dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69: 115–117.
Meyer, W. H., Schell, M. J., Kumar, A. P. M., Rao, B. N., Green, A. A., Champion, J. & Pratt, C. B. (1987). Thoracotomy for pulmonary metastatic osteosarcoma: an analysis of prognostic indicators of survival. Cancer 59: 374–379.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V. & Rosen, G. (1992). Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan–Kettering experience. J Clin Oncol 10: 5–15.
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R. & Magrath, I. (1987). Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5: 1191–1198.
Morgan, E., Baum, E., Bleyer, W. A., Movassaghi, N., Provisor, A., Lampkin, B., Lukens, J., Griffin, T., White, H., Fryer, C., Telander, R., Sather, H. & Hammond, D. (1984). Treatment of patients with metastatic osteogenic sarcoma: a report from the childrens cancer study group. Cancer Treat Rep 68: 661–664.
Muller-Weihrich, S., Henze, G., Odenwald, E. & Riehm, H. (1985). BFM trials for childhood non-Hodgkin’s lymphoma. In Malignant Lymphomas and Hodgkins Disease: Experimental and Therapeutic Advances, Cavalli F, Bonadonna G, Rozencweigh M (eds), pp. 633–642, Nijhoff: Boston
Nitschke, R., Starling, K. A., Vats, J. & Bryan, H. (1978). Cis-diamine-dichloroplatinum (NSC-119875) in childhood malignancies. A Southwest Oncology Group Study. Med Pediatr Oncol 4: 127–132.
O’Dwyer, P. J., Leyland-Jones, B., Alonso, M., Marsoni, S. & Wittes, R. E. (1985). Etoposide (VP16-213) current status of an active anticancer drug. New Engl J Med 312: 692–700.
Ornadel, D., Souhami, R. L., Whelan, J., Nooy, M., Ruiz de Eliviva, C., Pringle, J., Lewis, I., Steward, W. P., George, R., Bridgewater, J., Wierzbicki, R. & Craft, A. W. (1994). Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: a phase II trial for the European Osteosarcoma Intergroup. J Clin Oncol 12: 1842–1848.
Parham, D. M., Pratt, C. B., Parvey, L. S., Webber, B. L. & Champion, J. (1985). Childhood multifocal osteosarcoma: clinical and radiological correlates. Cancer 55: 2653–2658.
Prasad, V. K., Lewis, I. J., Aparicio, S. R., Heney, D., Hale, J. P., Bailey, C. C. & Kinsey, S. E. (1996). Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 27: 149–155.
Rosen, G. (1993). An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. Cancer Treat Res 62: 49–54.
Saeter, G., Hoie, J., Stenwig, A. E., Johansson, A. K., Hannisdal, E. & Solheim, O. P. (1995). Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75: 1084–1093.
Schaller, R. T., Haas, J., Schaller, J., Morgan, A. & Bleyer, A. (1982). Improved survival in children with osteosarcoma following resection of pulmonary metastases. J Paediatr Surg 17: 546–550.
Skinner, K. A., Eilber, F. R., Carmack Holmes, E., Eckardt, J. & Rosen, G. (1992). Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma. Arch Surg 127: 1065–1071.
Snyder, C. L., Saltzman, D. A., Ferrell, K. L., Thompson, R. C. & Leonard, A. S. (1991). A new approach to the resection of pulmonary osteosarcoma metastases – results of aggressive metastatectomy. Clin Orthop Related Res 270: 247–253.
Solheim, O. P., Saeter, G., Elomaa, I. & Alvegard, T. A. (1992). The treatment of osteosarcoma: present trends. Ann Oncol 3(suppl. 2): 7–11.
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooji, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., Van Glabbeke, M. & Machin, D. (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350: 911–917.
Tabone, M-D, Kalifa, C., Rodary, C., Raquin, M., Valteau-Couanet, D. & Lemerle, J. (1994). Osteosarcoma recurrences in paediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12: 2614–2620.
Ward, W., Mikaelian, K., Dorey, F., Mirra, J., Sassoon, A., Holmes, E. C., Eilber, F. R. & Eckardt, J. J. (1994). Pulmonary metastases of stage 11B extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12: 1849–1858.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Michelagnoli, M., Lewis, I., Gattamaneni, H. et al. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. Br J Cancer 79, 1174–1178 (1999). https://doi.org/10.1038/sj.bjc.6690187
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690187
Keywords
This article is cited by
-
The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma
Pediatric Drugs (2014)